{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "17655159", "DateCompleted": {"Year": "2008", "Month": "08", "Day": "04"}, "DateRevised": {"Year": "2016", "Month": "11", "Day": "24"}, "Article": {"ArticleDate": [], "Language": ["chi"], "ELocationID": [], "Journal": {"ISSN": "1001-5302", "JournalIssue": {"Volume": "32", "Issue": "10", "PubDate": {"Year": "2007", "Month": "May"}}, "Title": "Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica", "ISOAbbreviation": "Zhongguo Zhong Yao Za Zhi"}, "ArticleTitle": "[Curative effect of Xianling Qianggu koufuye on postmenopausal osteoporosis].", "Pagination": {"StartPage": "965", "EndPage": "997", "MedlinePgn": "965-8, 997"}, "Abstract": {"AbstractText": ["To study the curative effects of Xianling Qianggu koufuye (XLQG) on postmenopausal osteoporosis in ovariectomized female rats.", "Sixty female Sprague-dawley rats aged 12-months were used, 50 of them were ovariectomized and randomly divided into 5 groups: ovariectomized (OVX), OVX + Nylestriol, OVX + XLQG (high dose, middle dose, low dose), and the others were sham-operated group. Rats were treated with drugs starting at the 45 day after the operation for 90 days. Double in vivo fluorochrome labeling was administered to all rats. At the end-point of study, the blood was collected to detecte the contents of ALP and StrACP in serum, and the fourth lumar vertebra (LV4) and femur bone sections were cut and stained for bone histomorphometric analyses, biomechanical analyses and BMP analyses.", "XLQGKFY decreased greatly the StrACP content, increased BMP and bone stiffness, and improved the bone biomechanical property.", "Xianling Qianggu koufuye has a curative effect on postmenopausal osteoporosis, which provides for clinical use."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Simcere Pharmaceutical Research Company Ltd, Nanjing 210042, China. wdc-nm1975@yahoo.com.cn"}], "Identifier": [], "LastName": "Wang", "ForeName": "Dong-Chun", "Initials": "DC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Tan", "ForeName": "Ai-Min", "Initials": "AM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Ma", "ForeName": "Shi-Pin", "Initials": "SP"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Liu", "ForeName": "Kang", "Initials": "K"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Zhongguo Zhong Yao Za Zhi", "NlmUniqueID": "8913656", "ISSNLinking": "1001-5302"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "Isoenzymes"}, {"RegistryNumber": "0", "NameOfSubstance": "Materia Medica"}, {"RegistryNumber": "EC 3.1.3.1", "NameOfSubstance": "Alkaline Phosphatase"}, {"RegistryNumber": "EC 3.1.3.2", "NameOfSubstance": "Acid Phosphatase"}, {"RegistryNumber": "EC 3.1.3.2", "NameOfSubstance": "Tartrate-Resistant Acid Phosphatase"}], "MeshHeadingList": [{"QualifierName": ["blood"], "DescriptorName": "Acid Phosphatase"}, {"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": ["blood"], "DescriptorName": "Alkaline Phosphatase"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Bone Density"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cockroaches"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": ["administration & dosage", "isolation & purification", "therapeutic use"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["blood"], "DescriptorName": "Isoenzymes"}, {"QualifierName": ["administration & dosage", "isolation & purification", "therapeutic use"], "DescriptorName": "Materia Medica"}, {"QualifierName": [], "DescriptorName": "Medicine, Chinese Traditional"}, {"QualifierName": ["blood", "drug therapy", "physiopathology"], "DescriptorName": "Osteoporosis"}, {"QualifierName": ["blood", "drug therapy", "physiopathology"], "DescriptorName": "Osteoporosis, Postmenopausal"}, {"QualifierName": [], "DescriptorName": "Ovariectomy"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Random Allocation"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": [], "DescriptorName": "Tartrate-Resistant Acid Phosphatase"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2007", "Month": "7", "Day": "28", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "8", "Day": "5", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "7", "Day": "28", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17655159"]}}], "PubmedBookArticle": []}